Fluorenone oxime is a synthetic organic compound with a structure based on the fluorenone molecule, modified by the addition of an oxime group. It is a crystalline solid with a melting point of 157-159 °C.
Fluorenone oxime is typically synthesized by reacting fluorenone with hydroxylamine hydrochloride in the presence of a base. The reaction proceeds via nucleophilic attack of the hydroxylamine on the carbonyl group of fluorenone, followed by dehydration to form the oxime.
Fluorenone oxime is of interest to researchers for several reasons. It is a valuable precursor in the synthesis of other organic compounds, including various heterocycles and bioactive molecules. Moreover, it exhibits interesting pharmacological properties, such as anti-inflammatory and anticancer activities. These properties have led to ongoing research exploring its potential therapeutic applications.
The presence of the oxime group in fluorenone oxime allows for the formation of coordination complexes with metal ions. This property has been investigated in the development of sensors for metal ions, particularly for heavy metals like mercury and lead.
Furthermore, fluorenone oxime is studied for its photochemical properties. It exhibits photochromism, meaning it undergoes a reversible change in color upon exposure to ultraviolet light. This property makes it potentially useful in applications such as optical switching and data storage.'
```
ID Source | ID |
---|---|
PubMed CID | 16543 |
CHEMBL ID | 1492999 |
SCHEMBL ID | 577391 |
MeSH ID | M0068972 |
Synonym |
---|
HMS1577D07 |
AC-4875 |
CBDIVE_014646 |
2157-52-0 |
nsc1988 |
fluoren-9-one, oxime |
nsc-1988 |
fluorenone oxime |
9-fluorenone oxime |
fluorenone-9-oxime |
9h-fluoren-9-one oxime |
brn 1871046 |
9-oximinofluorene |
einecs 218-471-8 |
nsc 1988 |
9h-fluoren-9-one, oxime |
9-fluorenone, oxime |
fluoren-9-one oxime |
MLS001181444 , |
smr000567249 |
STK387446 |
n-hydroxy-9h-fluoren-9-imine |
n-fluoren-9-ylidenehydroxylamine |
AKOS001062418 |
F0023 |
NCGC00246633-01 |
unii-bqn5ah5vzj |
bqn5ah5vzj , |
4-07-00-01631 (beilstein handbook reference) |
AE-641/02574026 |
A815492 |
HMS2870P13 |
n-fluoren-9-ylidene-hydroxylamine |
SR-01000390929-3 |
sr-01000390929 |
FT-0621653 |
SCHEMBL577391 |
CHEMBL1492999 |
Q-101163 |
CRNNFEKVPRFZKJ-UHFFFAOYSA-N |
DTXSID50175919 |
mfcd00016356 |
n-(9h-fluoren-9-ylidene)hydroxylamine |
SR-01000390929-1 |
9h-fluoren-9-oneoxime |
Z49568437 |
fluorenonoxim |
DS-6618 |
H11335 |
SB67052 |
[2-(4-bromo-phenyl)-oxazol-4-yl]methanol |
EN300-15688 |
CS-W015721 |
SY049700 |
9-Fluorenone oxime was found to be an excellent substrate for a partially purified rat liver aryl sulfotransferase preparation.
Excerpt | Reference | Relevance |
---|---|---|
"9-Fluorenone oxime was found to be an excellent substrate for a partially purified rat liver aryl sulfotransferase preparation." | ( Rat liver aryl sulfotransferase-catalyzed sulfation and rearrangement of 9-fluorenone oxime. Mangold, BL; Mangold, JB; Spina, A, 1986) | 1.06 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 37.9330 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
Smad3 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 4.4668 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 28.1838 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 50.1187 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 35.4813 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 30.1313 | 0.0601 | 10.7453 | 37.9330 | AID485367 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Hsf1 protein | Mus musculus (house mouse) | EC50 (µMol) | 260.0000 | 0.1600 | 24.4900 | 236.5000 | AID435004 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Hsf1 protein | Mus musculus (house mouse) | AbsAC40_uM | 15.7800 | 1.2400 | 12.4600 | 25.2000 | AID602296 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (22.22) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.29) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |